Georgia's Online Cancer Information Center


back

Hematopoietic Malignancies Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Hematopoietic Malignancies
Cancer Type = Hematopoietic Malignancies
NCI ID Cancer Type Trial Name
There are currently 71 active Hematopoietic Malignancies clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
NCORP Trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT01351545
Protocol IDs
10-CBA
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04409301
Protocol IDs
AFLAC4875-19
NCI-2019-08591
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05482971
Protocol IDs
EXCEED ET / A22-301
NCI-2023-00605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
6.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
7.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
8.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
9.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
10.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT05487170
Protocol IDs
RNK05047-01
NCI-2022-09252
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
12.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
13.
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
14.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
15.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03391778
Protocol IDs
208750
NCI-2018-01288
ADP-0000-002
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
17.
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Cancer Type
COVID-19, Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04659135
Protocol IDs
Pro00014181
NCI-2021-00737
18.
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04105010
Protocol IDs
DZ2019J0005
NCI-2021-03769
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03564587
Protocol IDs
CHOA4223-17
NCI-2018-00736
IRB00099050
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
20.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05039073
Protocol IDs
WINSHIP5260-21
NCI-2021-01655
STUDY00002348
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
NCI-2013-01275
U10CA021115
E4412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT01499394
Protocol IDs
TCBIO-001-0710
Treatment Sites (1)
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
23.
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
24.
NCORP Trial
CIBMTR Research Database
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT01166009
Protocol IDs
NMDP IRB-1999-0021
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
25.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
26.
NCORP Trial
Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04242095
Protocol IDs
A151804
A151804
NCI-2019-07113
27.
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCT ID
NCT03397706
Protocol IDs
VT3996-201
NCI-2018-00416
28.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
29.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
31.
Faith-Based African American Cancer Survivorship Storytelling
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03082612
Protocol IDs
EU3999-17
NCI-2017-00980
IRB00093110
Treatment Sites (1)
Grady Memorial Hospital
Atlanta
32.
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT00785525
Protocol IDs
PBSC
NCI-2014-00012
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
FS118 First in Human Study in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Hematopoietic Malignancies
NCT ID
NCT03440437
Protocol IDs
FS118-17101
NCI-2018-01062
34.
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma
NCT ID
NCT04824794
Protocol IDs
GCT3014-01
NCI-2021-05589
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02530034
Protocol IDs
2014-0057
NCI-2015-02131
P-TRP-2447-14
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
36.
Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
37.
Imaging and Blood Biomarker Evaluation of Engraftment after Allogeneic Hematopoietic Stem Cell Transplant, REVEAL Study
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03541889
Protocol IDs
OUHSC4891-19
NCI-2020-13763
38.
Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Sarcoma
NCT ID
NCT04416568
Protocol IDs
20-041
NCI-2020-04573
39.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
40.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
41.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
42.
Maintenance Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02498951
Protocol IDs
IRB00011601
NCI-2015-01014
ML29496
43.
Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04089358
Protocol IDs
ALTE2031
ALTE2031
COG-ALTE2031
NCI-2020-01916
44.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04676087
Protocol IDs
WINSHIP5101-20
NCI-2020-06013
45.
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type
Hematopoietic Malignancies, Melanoma
NCT ID
NCT03589339
Protocol IDs
1100
NCI-2019-03108
NBTXR3-1100
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
46.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
47.
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03816345
Protocol IDs
10204
10204
NCI-2019-00241
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
NCORP Trial
Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
49.
Olanzapine versus Megestrol Acetate for the Treatment of Loss of Appetite among Advanced Cancer Patients
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04939090
Protocol IDs
A222004
A222004
A222004
NCI-2021-03303
50.
Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03598998
Protocol IDs
17501
NCI-2018-01420
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
51.
Predicting Childhood Cancer Survivors' Transition Readiness and Transfer Outcomes, SURV Transfer Outcomes Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04257058
Protocol IDs
CHOA4312-18
NCI-2020-07495
52.
Psilocybin Combined with Multidisciplinary Palliative Care in Demoralized Cancer Survivors with Chronic Pain
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT05506982
Protocol IDs
EU5206-20
NCI-2020-13913
STUDY00001905
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
53.
Radiosurgery before Surgery for the Treatment of Brain Metastases
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04895592
Protocol IDs
RAD5234-21
NCI-2021-02761
STUDY00001896
54.
Rifaximin in Preventing Infections in Participants with Blood Cancer Undergoing Hematopoietic Stem Cell Transplantation
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03529825
Protocol IDs
CHOA4273-18
NCI-2018-00596
IRB00101158
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
55.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
56.
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT02636855
Protocol IDs
ADP-0000-001
NCI-2016-01399
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
57.
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04865419
Protocol IDs
D8241C00001
NCI-2021-08915
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
58.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCT ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
59.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
60.
SurvivorLink in Improving Quality of Life in Cancer Survivors and Caregivers
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03543852
Protocol IDs
RSPH-AFLAC4297-18
NCI-2018-00396
IRB00101506
61.
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03394365
Protocol IDs
ATA129-EBV-302
NCI-2018-00043
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
62.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03984448
Protocol IDs
A051701
A051701
NCI-2019-03711
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
64.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04803201
Protocol IDs
A051902
A051902
NCI-2021-01380
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
65.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
66.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
67.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
68.
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04551066
Protocol IDs
INCB 50465-313/LIMBER-313
NCI-2021-01110
INCB 50465-313
69.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02495415
Protocol IDs
FEN T-14
NCI-2015-01195
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
70.
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type
Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04847453
Protocol IDs
10440
10440
NCI-2021-03038
PHI-124
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
71.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03842696
Protocol IDs
UMCC 2018.081
NCI-2019-04695
HUM00147796
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.